🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseMASH biomarker panel — OWLiver, NIS4, ELF vs biopsy correlation

MASH biomarker panel — OWLiver, NIS4, ELF vs biopsy correlation

MASHdoc_SA Fri, May 29, 2026 at 1:42 AM 7 replies 314 viewsPage 1 of 2
MASHdoc_SA
Member
456
2,345
Aug 2024
San Antonio, TX
May 29, 2026 at 1:42 AM#1

Writing this once so I can stop repeating it across threads. It is about the baseline and follow-up panel, and it is deliberately narrow — everything I am not confident about is marked as such.

What is actually established

A defensible baseline is short: HbA1c and fasting glucose, a lipid panel with ApoB if you can get it, ALT and AST, creatinine with eGFR, TSH, ferritin and B12, and a full blood count. That set catches the things that change, the things that explain symptoms, and the things that alter the prescribing decision. Almost everything else on the long circulating lists is either invariant, uninterpretable without a specific question, or an incidental finding waiting to cause an unnecessary workup.

The condition it depends on

One addition: if the lab changes analytical platform between your draws, the comparison breaks and nobody tells you. It is worth asking when a value moves inexplicably.

The practical version

Post reference ranges alongside numbers when you share them. Units differ by country — glucose and lipids especially — and half the confusion in these threads is unit mismatch rather than disagreement.

What I am not sure about

What would genuinely help is knowing how often to repeat it, because quarterly seems to be the convention and I cannot find the reasoning. Not looking for reassurance. Looking for the part I have got wrong.

— MASHdoc_SA · corrections welcome and will be edited into this post with credit
1 21TirzTom
Reply Quote Save Share Report
Dr.LipidDallas
VIP Member
2,678
14,567
Dec 2023
Dallas, TX
May 29, 2026 at 1:56 AM#2
MASHdoc_SA said:
A defensible baseline is short: HbA1c and fasting glucose, a lipid panel with ApoB if you can get it, ALT and AST, creatinine with eGFR, TSH, ferritin…

No disagreement with MASHdoc_SA. One condition attached. The single most useful discipline is bringing the whole panel to a clinician rather than one flagged value. One out-of-range result in isolation generates anxiety and unnecessary tests; the same result next to the trend and the rest of the panel usually generates a shrug.

50 20wei_SG, cory_ATX, lori_vegas and 47 others
Reply Quote Save Share Report
JennaRN
Senior Member
1,987
8,923
Mar 2024
Colorado
Online
May 29, 2026 at 2:10 AM#3
MASHdoc_SA said:
A defensible baseline is short: HbA1c and fasting glucose, a lipid panel with ApoB if you can get it, ALT and AST, creatinine with eGFR, TSH, ferritin…

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. I would drop the "get everything" instinct further than this thread does. Every extra test is another chance at a false positive, and incidental findings have their own cost in scans, biopsies and worry.

49 19BiostatsBrad, PeptideSynthNJ, Dr.KarenChen and 46 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
JenPlateau
Member
234
890
Nov 2024
Missouri
May 29, 2026 at 2:24 AM#4

Short answer first, then the reasoning. Quarterly for the first year is convention rather than evidence, and it is defensible for a simple reason: it is roughly the interval over which HbA1c becomes informative again, since it reflects about three months of glycaemia. After the first year, and once doses are stable, annual is reasonable unless something specific is being followed.

48 18FitDadDave, RunnerRach, TrialNerd_Beth and 45 others
Reply Quote Save Share Report
ricardo_MIA
Member
378
1,678
Sep 2024
Miami, FL
May 29, 2026 at 3:36 AM#5
Dr.LipidDallas said:
The single most useful discipline is bringing the whole panel to a clinician rather than one flagged value.

Agreed, and ALT falling is not the same as fibrosis improving. Enzymes are a crude proxy; FIB-4 or elastography is what tells you about the thing that matters.

47 17ChrisMacros, KetoKyle, CanadaChris and 44 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register